However upon comparison of 5 different CRC cell lines we could not relate the differences in sensitivity to SHIP2 inhibition to PIK3CA mutational status, suggesting that SHIP2 inhibition could be a target for treatment of CRC, irrespective of variation in their existing mutations. This evidence concerns the gene PIK3CA and colorectal carcinoma.